Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Reports Fiscal 2012 First Quarter Financial Results
Arrowhead Reports Fiscal 2012 First Quarter Financial Results PASADENA, Calif. — February 9, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2012 first quarter ended
View HTML
Toggle Summary Arrowhead to Report Fiscal 2012 First Quarter Financial Results
Conference call Scheduled for Thursday, February 9, 2012
View HTML
Toggle Summary Alnylam and Arrowhead Form Collaboration and Licensing Agreement
– Arrowhead Receives License from Alnylam to Develop RNAi Therapeutic Toward Hepatitis B Virus (HBV) – – Alnylam Gains Access to Arrowhead's Dynamic Polyconjugate (DPC) Delivery Technology for "Alnylam 5x15" Target –
View HTML
Toggle Summary Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial
Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial PASADENA, Calif. — January 4, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application
View HTML
Toggle Summary Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results
Arrowhead Reports Fiscal 2011 Fourth Quarter and Year-End Financial Results PASADENA, Calif. — December 20, 2011 — Arrowhead Research Corporation (NASDAQ: ARWRD) , a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth
View HTML
Toggle Summary Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors
Arrowhead Appoints Michael S. Perry, DVM, Ph.D. to Board of Directors PASADENA, Calif. — December 19, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S.
View HTML
Toggle Summary Arrowhead to Report Fiscal 2011 Fourth Quarter and Year-End Financial Results
Conference call Scheduled for Tuesday, December 20, 2011
View HTML
Toggle Summary Arrowhead Research Publishes White Paper on RNAi Delivery Technology Acquired from Roche
- A Well-Designed and Powerful Solution to the siRNA Delivery Challenge -
View HTML
Toggle Summary Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility
Arrowhead Research Appoints Drs. David Lewis and David Rozema to Lead Operations at Madison, WI Facility PASADENA, Calif. — November 23, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR) , a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today
View HTML
Toggle Summary Arrowhead Research Announces 1-for-10 Reverse Stock Split
Arrowhead Research Announces 1-for-10 Reverse Stock Split PASADENA, Calif. — November 16, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the implementation of a 1-for-10 reverse
View HTML